Loading…
← CockpitCompetitor Analysis › 002790.KS AMOREPACIFIC HoldingsOpen in the cockpit ↗

AMOREPACIFIC Holdings002790.KSCompetitor analysis, valuation and peers

South Korea · KRW·Consumer Staples›Household/Personal Care

Holding company atop Amorepacific Corp, Korea's top cosmetics maker behind Sulwhasoo, Innisfree and Laneige.

Momentum leader 89
Mkt cap
$1.61B
US dollars, full cap
Free float
33%
of shares outstanding
$/day
$2.00M
20-day average traded
Fwd P/E
8.5×
forward earnings
ROIC−WACC
-1.1 pp
WACC 5.4%
Hurdle
-4 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · KRW₩27,000
1D+0.4%
1W+2.5%
1M+5.7%
3M+2.5%
6M+1.9%
YTD+1.9%
1Y+9.5%
ATR %3.8%
52w lowhigh23.9% off high

What AMOREPACIFIC does

Holding company atop Amorepacific Corp, Korea's top cosmetics maker behind Sulwhasoo, Innisfree and Laneige.

Holds shares in Amorepacific Corp and other group companies, so its own income is dividends and brand-royalty payments from them, and its consolidated results largely mirror the operating company. Created in 2007 when the group split into a holding company and an operating company, and controlled by the founding Suh family.

Products and services

  • Amorepacific Corp stake
  • Other group affiliates

Where it sits in the supply chain

  • Consumer holding company
  • Cosmetics/beauty group
  • Group holding structure

What could go right

  • Amorepacific Corp brand recovery (Laneige, Sulwhasoo)

What could go wrong

  • Holding-company discount
  • China/duty-free demand swings at subsidiary

Moat: none. Pure holding company; value depends on operating subsidiary Amorepacific Corp.

Headquarters: Seoul, South Korea · Founded: 2006 · Employees: 60

Named competitors

AMOREPACIFIC at a glance

Size AMOREPACIFIC (002790.KS) is a South Korea Consumer Staples company (Household/Personal Care) with a market value of $1.61B, the 164th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩27,000 on 18 Nov 2026.

Performance Over six months the shares gained 1.9%, against +7.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 8.6% over the last twelve months (peer median +5.6%); the operating margin is 9.0% (peer median 10.5%).

Valuation It trades at 8.5× forward earnings against a peer median of 19.0× (cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.1 points below its cost of capital (5.4% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 109002790.KS 105
Six months, rebased to 100: AMOREPACIFIC against the median of its 20 peers (local-currency closes).

AMOREPACIFIC financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩4.94T₩4.62T₩4.26T₩4.02T₩4.49T
Revenue growth—+9%+6%-11%—
Gross profit₩3.47T₩3.13T₩2.87T₩2.67T₩2.91T
EBITDA₩714B₩648B₩517B₩411B₩595B
Net income₩134B₩104B₩230B₩119B₩62.2B
Free cash flow₩431B₩553B₩297B₩202B₩63.8B
Capital expenditure₩124B₩107B₩117B₩232B₩160B
Total debt₩263B₩346B₩452B₩374B₩367B

Quarterly statements and history in the cockpit →

AMOREPACIFIC competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%6003156039833009573013717956ICOS003006ENREMAMILTDEPC49271618906993492226982145483650PGHH2367002790.KS6-month return →1-month return →
Up and to the right = strong over both horizons. AMOREPACIFIC is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×6003156039833009573013717956ICOS003006ENREMAMILTDEPC4927161890699326982145483650PGHH23672657002790.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AMOREPACIFIC is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6003153009573013717956ICOS003006ENREMAMILTD16189026982145483650PGHH23672657002790.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. AMOREPACIFIC is the large dot.

AMOREPACIFIC competitors and peer comparison

Head to head with its named competitors (002790.KS vs 051900.KS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
AMOREPACIFIC 002790.KS$1.61B+2%+9%9%8.5×-5.7%
LG H&h 051900.KS$2.81B-14%-3%3%23.1×-4.6%

How AMOREPACIFIC compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AMOREPACIFIC against its 20 peers (data as of 18 Nov 2026)
Measure002790.KSPeer medianRank in peer set
1-month return+5.7%+1.1%7th highest of 21
6-month return+1.9%+7.1%10th lowest of 21
Distance from 52-week high-23.9%-26.2%9th highest of 21
Revenue growth (TTM)+8.6%+5.6%9th highest of 21
Operating margin9.0%10.5%9th lowest of 21
Forward P/E8.5×19.0×cheapest of 21
Growth the price implies (Req g, 7 yrs)-5.7%3.4%4th least demanding of 17
Growth delivered (Del g)-1.3%+13.4%2nd lowest of 17
Hurdle (Req g minus delivered)-4.4 pp-5.9 pp8th most demanding of 17
ROIC minus cost of capital-1.1 pp+6.8 pp5th lowest of 20
EV / EBITDA6.3×10.2×2nd cheapest of 15
Net debt / EBITDA-2.1×-1.2×5th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
AMOREPACIFIC 002790.KSSouth Korea$1.61B+2%+9%9%8.5×-5.7%-1.3%
Shanghai Jahwa United 600315.SSChina$1.61B-15%+9%2%15.4×15.3%-2.1%
Guangdong Marubi Biotechnology 603983.SSChina$1.62B+9%-6%2%45.5×n/an/a
Yunnan Botanee Bio-Technology 300957.SZChina$1.69B-33%+7%9%19.1×2.6%+15.3%
Harbin Fuerjia Technology 301371.SZChina$1.51B-39%+28%20%21.4×7.5%+3.6%
Pigeon 7956.TJapan$1.76B+26%+8%13%27.9×-2.4%+1.9%
Intercos ICOS.MIItaly$1.43B+12%-5%9%18.9×4.3%+11.5%
Chongqing Baiya Sanitary Products 003006.SZChina$1.35B+27%0%3%37.3×28.8%+22.8%
Energizer ENRUnited States$1.94B+71%0%17%9.1×-5.1%-0.5%
Emami EMAMILTD.NSIndia$1.94B-5%+13%20%23.4×21.5%+5.6%
Edgewell Personal Care EPCUnited States$1.30B+67%-10%7%14.2×n/an/a
Pola Orbis 4927.TJapan$2.04B+15%+1%11%30.6×-2.0%-0.7%
Kolmar Korea 161890.KSSouth Korea$2.05B+14%+16%10%14.3×-1.6%+15.5%
Blue Moon 6993.HKHong Kong$2.07B-4%-2%-2%103.3×n/an/a
KOSE 4922.TJapan$2.16B+16%+4%5%29.9×n/an/a
Softcare 2698.HKHong Kong$2.20B+5%+25%25%14.4×9.1%+20.9%
Shanghai Chicmax Cosmetics 2145.HKHong Kong$1.17B-42%+23%8%14.4×-6.1%+21.2%
d'Alba Global 483650.KSSouth Korea$1.13B-55%+49%22%12.0×-6.6%+53.0%
Procter & Gamble Hygiene & Health Care PGHH.NSIndia$2.37B-30%-2%24%27.0×21.2%+7.4%
Giant Biogene 2367.HKHong Kong$2.47B-32%-10%32%8.6×-10.7%+34.9%
Shanghai Forest Cabin Cosmetics 2657.HKHong Kong$1.04B+15%+74%18%11.8×11.3%+49.0%

Questions

Who are AMOREPACIFIC's main competitors?
Named competitors: LG H&H (051900.KS). The cockpit's measured peer set (industry) also includes Shanghai Jahwa United (600315.SS), Guangdong Marubi Biotechnology (603983.SS), Yunnan Botanee Bio-Technology (300957.SZ), Harbin Fuerjia Technology (301371.SZ), Pigeon (7956.T), Intercos (ICOS.MI).
Is AMOREPACIFIC expensive compared with its peers?
On forward p/e it trades at 8.5× against a peer median of 19.0×, cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has AMOREPACIFIC stock performed?
Over six months to 18 Nov 2026 the shares returned +1.9% against +7.1% for the median peer; over one year +9.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.